The acquisition expands Thermo Fisher's portfolio of reagents and other consumables for the molecular biology research and diagnostics markets through the addition of its proprietary DNA polymerases, Phire and Phusion, and high-speed miniaturized thermal cyclers, plastic tubes and plates.
These products complement Thermo Scientific's recently launched Solaris qPCR gene expression assays. The company said that combining its gene-specific MGB-based probes with the advanced enzyme performance from Finnzymes, will further enhance qPCR assay technology.
Finnzymes will be integrated primarily into Thermo Fisher's Analytical Technologies segment, with some equipment and consumables product lines being added to the Laboratory Products and Services segment. The transaction is expected to close during the first quarter of 2010.
Marc Casper, president and chief executive officer of Thermo Fisher Scientific, said: "The addition of Finnzymes' innovative enzyme portfolio and unique PCR instrument platform strengthens our broad range of life science reagents and consumables, as well as our specialty diagnostics product offering. This combination brings together key complementary technologies for molecular biology and diagnostics, allowing us to create significant value for our customers."
Finnzymes provides solutions for high-performance polymerase chain reaction (PCR), reverse transcription-PCR (RT-PCR) and real-time quantitative PCR (qPCR).